The Italian government “has started talks with the American company Moderna, the Swiss company Novartis and the Italian ReiThera to produce mRNA-based vaccines against Covid-19 in our country”. This is what the ‘Financial Times’ writes, with a reconstruction that follows the news circulated recently on the possibility that various industrial plants in the pharmaceutical sector in our territory are involved in the production of anti-Covid vaccines. Vaccines that should not remain within national borders, but would be destined to increase the availability of the European Union.
“The recent talks with Novartis and ReiThera – says the newspaper – provide for the possibility of producing in Italy the mRna vaccine developed by the German CureVac. In March Novartis signed a preliminary agreement with CureVac for the production, the vaccine is still in phase 3 of the trial but the German company has stated that by May or June it could be approved by the EMA. ReiThera is producing its vaccine, which is still in phase 2 and is based on a viral vector technology (adenovirus) “. Novartis, ReiThera and CureVac “did not want to comment”, highlights the FT which reports that the talks “between Novartis, ReiThera and the Italian government would be at an early stage, and may not lead to a final agreement”.
Also according to the British business daily, “Prime Minister Mario Draghi also spoke directly with Moderna’s CEO, Stéphane Bancel, without however reaching an even preliminary agreement because the US company would not be able to supervise the transfer. the technology necessary for Italian production sites or to equip them with the skills necessary to increase production “. Moderna declined to comment on the indiscretion.
If what emerges from the reconstruction of the ‘Financial Times’ were to succeed, our country could increase the production capacity of vaccines with mRna technology and satisfy the whole of Europe. “The EU seems to move away from the viral vector vaccines based on the adenovirus produced by AstraZeneca and Johnson & Johnson – recalls the article – many countries have limited or banned the use of the first, since Ema, the European Medicines Agency , acknowledged that it could cause a very rare side effect linked to blood clotting; of the second – continues the analysis – distribution has been suspended for now “, waiting for the FDA and EMA to decide on the adverse events recorded on six US citizens who have had thrombotic episodes after being vaccinated.